Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)1990-472XФедеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации92910.18499/1990-472X-2006-0-25-69-78Original ArticleINTERRELATION OF EFFECTIVENESS OF ANTIAGREGANT THERAPY OF ACETYLSALICYLIC ACID AND TOLERANCE TO PHYSICAL LOAD IN PATIENTS WITH STABLE VENTRICARDIUM OF STRESSDemyanenkoO V-VishnevskyV I-Oryol State University1509200625697813032020Copyright © 2006, Научно-медицинский вестник Центрального Черноземья2006The aim of the study was to evaluate the efficacy of various forms of acetylsalicylic acid (ACA) on aggregation activity of platelets in patients with ischemic heart disease: stable angina pectoris with a sensitivity factor to disaggregant therapy (Ra%) and to prove the presence of correlations between biochemical and clinical resistance to ASA 58 patients with stable angina pectoris of II-III FC were observed. ADP-induced platelet aggregation and patient tolerance to exercise were evaluated against the background of administration of Thrombone ACC 50 and ASA 125 mg / day. Criteria for the efficacy of antiplatelet therapy (AAT) using a sensitivity factor for disaggregant therapy (Ra%) and an index of the degree of maximum aggregation (Amax) are proposed. Using these criteria, insufficient sensitivity was found in 34.5% and resistance in 27.6% of patients with Trombo ACC 50, as well as lack of sensitivity in 17.2% and resistance in 20.7% of patients on the background of administration of ASA 125 mg /day. The relationship between the efficacy of AAT and the tolerance of patients to physical activity has been revealed. Thus, the obtained results indicate the validity of the use of the introduced criteria for the effectiveness of AAT (Ra% and Amax) and the presence of correlations between biochemical and clinical resistance to ASA drugs.angina pectorisantiplatelet therapyacetylsalicylic acidangina pectorisantiplatelet therapyacetylsalicylic acidстенокардия напряженияантиагрегантная терапияацетилсалициловая кислота[Аронов, Д.М. Функциональные пробы в кардиологии / Д.М.Аронов, В.П.Лупанов. - М: «МЕДпресс-информ», 2003. - 295с.][Люсов, В.А. Метод графической регистрации агрегации тромбоцитов и изменение ее при ишемической болезни сердца / В.А.Люсов, Ю.Б.Белоусов // Лаб. дело. - 1971. - №8. - С.459-461.][Оганов, Р.Г. Новые подходы к лечению больных стабильной ишемической болезнью сердца / Р.Г. Оганов, Ю.М. Поздняков, Ю.А. Карпов // Кардиология. - 2004. - №10. - С.95-101.][Поляков, А.Е. Метод исследования агрегационной функции тромбоцитов / А.Е.Поляков, В.А.Черняк // Лаб. дело. - 1988. - №1. - С.19-20.][Aspirin resistance isassociated with a high incidence if myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment / W.H.Chen, P.Y.Lee, W.Ng et al. // J. Am. Coll. Cardiol. - 2004. - Vol.43. - P.1122-1126.][Aspirin Use in Older Patients With Heart Failure and Coronary Artery Disease / F.A.Masoudi, P.Wolfe, E.P.Havranek, S.S.Rathore // J. Am. Coll. Cardiol. - 2005. - Vol.46. - P.955-962.][Bhatt, D. Scientific and therapeutic advances in antiplatelet therapy / D.Bhatt, E.Topol // Nature Reviews. - 2003. - Vol.2. - P.15 - 28.][Effect of atorvastatin on C-reactive protein in patients with acute coronary syndromes: a substudy of the MIRACL trial (abstract) / S.Kinlay, N.Rafai, P.Libby et al. // J. Am. Coll. Cardiol. - 2002. - Vol.39. - P.322-323.][Eikelboom, J. W. Aspirin Resistance: A New Independent Predictor of Vascular Events? / J. W. Eikelboom // J. Am. Coll. Cardiol. - 2003. - Vol.41. - P.966-974.][European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. 3rd Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. (Constituted by representatives of eight societies and by invited experts // Eur. Heart J. - 2003. - Vol.24. - P. 1601-1610.][Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators / P.M.Ridker, N.Rifai, M.A.Pfeffer et al. //Circulation. - 1999. - Vol.100. - P.230-235.][Mason, P.J. Aspirin Resistance and Atherothrombotic Disease / P.J.Mason, A. K.Jacobs, J. E.Freedman // J. Am. Coll. Cardiol. - 2005. - Vol.46. - P.986-993.]